Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 3 (2008), Issue 3 (March)

1. Effect of a school-entry vaccination requirement on racial and ethnic disparities in hepatitis B immunization coverage levels among public school students.
   Pediatrics, 121(3): e547-52. [Abstract] [Full-text]
2. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention.
   J Med Virol, 80(4): 646-58. [Abstract] [Full-text]
3. Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.
   J Med Virol, 80(4): 632-9. [Abstract] [Full-text]
4. Diversity of hepatitis C virus genotype 1b in Buenos Aires, Argentina: description of a new cluster associated with response to treatment.
   J Med Virol, 80(4): 619-27. [Abstract] [Full-text]
5. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005.
   J Med Virol, 80(4): 640-5. [Abstract] [Full-text]
6. Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
   J Med Virol, 80(4): 628-31. [Abstract] [Full-text]
7. High prevalence of genotype 4 among hepatitis C virus-infected intravenous drug users in north-eastern Poland.
   J Med Virol, 80(4): 615-8. [Abstract] [Full-text]
8. Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection.
   J Med Virol, 80(4): 607-14. [Abstract] [Full-text]
9. Simultaneous detection of hepatitis C virus core antigen and antibodies in Saudi drug users using a novel assay.
   J Med Virol, 80(4): 603-6. [Abstract] [Full-text]
10. Improved detection of natural hepatitis B virus surface antigen (HBsAg) mutants by a new version of the VITROS HBsAg assay.
    J Med Virol, 80(4): 598-602. [Abstract] [Full-text]
11. Can the serological status of anti-HBc alone be considered a sentinel marker for detection of occult HBV infection?
    J Med Virol, 80(4): 577-82. [Abstract] [Full-text]
12. Transgenic mice replicating hepatitis B virus but lacking expression of the major HBsAg.
    J Med Virol, 80(4): 583-90. [Abstract] [Full-text]
13. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool.
    Hepatology, 47(3): 937-48. [Abstract] [Full-text]
14. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hepatology, 47(3): 844-53. [Abstract] [Full-text]
15. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.
    Hepatology, 47(3): 817-26. [Abstract] [Full-text]
16. A molecular chaperone glucose-regulated protein 94 blocks apoptosis induced by virus infection.
    Hepatology, 47(3): 854-66. [Abstract] [Full-text]
17. Interferon regulatory factor-3 activation, hepatic interferon-stimulated gene expression, and immune cell infiltration in hepatitis C virus patients.
    Hepatology, 47(3): 799-809. [Abstract] [Full-text]
18. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging.
    Hepatology, 47(3): 949-57. [Abstract] [Full-text]
19. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C.
    Hepatology, 47(3): 789-98. [Abstract] [Full-text]
20. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.
    Hepatology, 47(3): 836-43. [Abstract] [Full-text]
21. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma.
    Hepatology, 47(3): 908-18. [Abstract] [Full-text]
22. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C.
    Hepatology, 47(3): 810-6. [Abstract] [Full-text]
23. Dentistry and the ethics of infection.
    J Med Ethics, 34(3): 184-7. [Abstract] [Full-text]
24. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis.
    Nat Clin Pract Gastroenterol Hepatol, 5(3): 172-6. [Abstract] [Full-text]
25. Molecular analysis and patterns of ALT and hepatitis C virus seroconversion in haemodialysis patients with acute hepatitis.
    Nephrology (Carlton), 13(3): 186-92. [Abstract] [Full-text]
26. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
    J Gastroenterol Hepatol, 23(3): 474-81. [Abstract] [Full-text]
27. Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma.
    J Gastroenterol Hepatol, 23(3): 459-66. [Abstract] [Full-text]
28. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    J Gastroenterol Hepatol, 23(3): 467-73. [Abstract] [Full-text]
29. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers.
    Gastroenterology, 134(3): 716-26. [Abstract] [Full-text]
30. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection.
    Gastroenterology, 134(3): 812-22. [Abstract] [Full-text]
31. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.
    Toxicology, 246(1): 2-8. [Abstract] [Full-text]
32. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
    Gut, 57(4): 531-6. [Abstract] [Full-text]
33. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
    Gut, 57(4): 500-6. [Abstract] [Full-text]
34. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Gut, 57(4): 516-24. [Abstract] [Full-text]
35. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C.
    Gut, 57(4): 507-15. [Abstract] [Full-text]
36. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
    Gut, 57(4): 525-30. [Abstract] [Full-text]
37. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis.
    Liver Int, 28(4): 494-8. [Abstract] [Full-text]
38. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection.
    Liver Int, 28(4): 486-93. [Abstract] [Full-text]
39. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.
    Liver Int, 28(4): 477-85. [Abstract] [Full-text]
40. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025.
    Liver Int, 28(4): 525-31. [Abstract] [Full-text]
41. Hepatoprotective effect of Arazyme on CCl4-induced acute hepatic injury in SMP30 knock-out mice.
    Toxicology, 246(2): 132-42. [Abstract] [Full-text]
42. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
    J Antimicrob Chemother, 61(4): 925-32. [Abstract] [Full-text]
43. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    J Antimicrob Chemother, 61(4): 919-24. [Abstract] [Full-text]
44. Hepatitis B virus escape mutants induced by antiviral therapy.
    J Antimicrob Chemother, 61(4): 766-8. [Abstract] [Full-text]
45. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
    Virology, 373(2): 329-41. [Abstract] [Full-text]
46. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity.
    Toxicol Appl Pharmacol, 228(1): 17-23. [Abstract] [Full-text]
47. Detection and characterization of focal liver lesions with contrast-enhanced ultrasonography in patients with hepatitis C-induced liver cirrhosis.
    Acta Radiol, 49(3): 251-7. [Abstract] [Full-text]
48. Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection.
    J Pediatr Gastroenterol Nutr, 46(4): 423-8. [Abstract] [Full-text]
49. Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study.
    J Med Imaging Radiat Oncol, 52(2): 130-3. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.